Close Menu

NEW YORK – Blueprint Medicines unveiled top-line data from its Phase I/II trial on pralsetinib (BLU-667) for the treatment of RET fusion-positive non-small cell lung cancer on Wednesday. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.